The European Medicines Agency is permitting Sanofi division Genzyme to produce Fabry disease medicine Fabrazyme at a Framingham, Mass., facility. The approval "represents an important milestone in our manufacturing recovery and a path toward unconstrained supply for all patients," said Genzyme CEO and President David Meeker.
The biotech firm still awaits FDA approval.

Full Story:

Related Summaries